Imricor Medical Systems, Inc.ASX: IMR

Q3 CY2026 Quarterly Activities Report & Form 10-Q Submission

· Issued by Imricor Medical Systems, Inc. via ASX

Filed with ASX · · 7 pages · English

Summary by 6ix AI

The report highlights the commencement of the U.S. commercial launch, with significant sales to leading children's hospitals for radiation-free cardiac procedures. Financially, the company reported revenue growth attributed to initial U.S. sales, with total cash holdings noted at a substantial amount.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

IMRICOR Q3 CY2026 QUARTERLY ACTIVITIES REPORT AND FORM 10-Q SUBMISSION Key Highlights U.S. Commercial Launch • U.S. commercial launch commenced, with Rady Children’s Hospital–San Diego becoming Imricor’s first commercial U.S. hospital customer, purchasing NorthStar to establish the...

Imricor Medical Systems, Inc. on 6ix

In the deck

Story so far

Earlier from Imricor Medical Systems

Later from Imricor Medical Systems

All Imricor Medical Systems news releases